<DOC>
	<DOCNO>NCT02610088</DOCNO>
	<brief_summary>The investigator set clinical trial compare effect dapagliflozin , sodium glucose co-transporter 2 inhibitor , gliclazide vascular function patient type 2 diabetes</brief_summary>
	<brief_title>Effect Dapagliflozin Vascular Functions Patients With Type 2 Diabetes Compared Gliclazide</brief_title>
	<detailed_description>Obesity , especially visceral/abdominal adiposity , associate diabetes increase cardiovascular risk . In previous randomize , double-blind , placebo-controlled study , dapagliflozin reduce total body weight , predominantly reduce fat mass , visceral adipose tissue sc adipose tissue type 2 diabetes . This study support caloric loss glycosuria , fluid loss , principally responsible decrease total body weight fat mass . In fact , several report prove inhibition SGLT2 improve β-cell function reduces body weight blood pressure . However , effect SGLT2 inhibitor lipid profile decide yet patient type 2 diabetes . Furthermore , data demonstrate effect SGLT2 inhibitor CV risk . Many system pathway involve development atherosclerosis arterial wall . Accumulating evidence suggest endothelial dysfunction play important role particularly first stage atherogenesis patient diabetes . Approaches design improve endothelial function may therefore additional therapeutic value prevention treatment atherosclerotic disease . Endothelial dysfunction relate decreased production bioavailability nitric oxide ( NO ) . Endothelial function measure several circulate biomarker NO , endothelin-1 non-invasive technique flow-mediated dilation ( FMD ) , skin laser doppler . Among , FMD know optimal tool . In addition , several noninvasive technique include measurement ankle-brachial index ( ABI ) , carotid intima-media thickness ( IMT ) pulse wave velocity ( PWV ) use evaluation atherosclerosis .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>Type 2 diabetes HbA1c ≥ 7.5 % screen visit Male female 40 70 year age Patients take metformin ( ≥ 1000 mg maximum tolerate dose ) 3 month BMI ≥23 kg/m² Estimated GFR ≥ 60 ml/min/1.73m² Patients acute coronary syndrome within 3 month prior screen visit Pregnant breast feed woman reproductiveage woman refuse contraception Type 1 diabetes , gestational diabetes , diabetes secondary cause Chronic hepatitis B C ( except healthy carrier HBV ) , liver disease ( AST/ALT &gt; 3fold upper limit normal ) Cancer within 5 year ( except squamous cell cancer , cervical cancer , thyroid cancer appropriate treatment ) except thyroid cancer carcinoma situ Other clinical trial within 30 day Alcohol abuse Contraindication SGLT2 inhibitor sulfonylurea</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Endothelial dysfunction</keyword>
	<keyword>Vascular function</keyword>
	<keyword>Dapagliflozin</keyword>
	<keyword>Gliclazide</keyword>
</DOC>